Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN1117 combinations in advanced gastric cancer
NCT02551055Phase 1Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of serabelisib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (7 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Dose Limiting Toxicity, Treatment-Emergent Adverse Events and 4 more. Started Oct 2015; status: terminated.
02
Drugs
serabelisib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02551055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02551055.